Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aortic endografts (EVAR/TEVAR) cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (139 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 598 | 33% |
| 2020 | 2 | 438 | 36% |
| 2021 | 5 | 409 | 39% |
| 2022 | 1 | 411 | 41% |
| 2023 | 3 | 421 | 43% |
| 2024 | 3 | 400 | 45% |
| 2025 from claims | – | 341 275–400 | 46% |
| 2026 forecast | – | 346 271–434 | 46% |
| 2027 forecast | – | 350 260–463 | 47% |
| 2028 forecast | – | 355 251–489 | 47% |
| 2029 forecast | – | 359 244–515 | 47% |
| 2030 forecast | – | 364 238–540 | 48% |
Endovascular abdominal and thoracic aortic repair. Professional codes (what the surgeon bills): CPT 34701, 34702, 34703, 34704, 34705, 34706, 33880, 33881; the hospital bills MS-DRG 268, 269, 213, 209.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New Jersey; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 7 | 818−5.7%/yr | −5.7%/yr | 0.5 | 0% | 860 in 2030+0.8%/yr |
| Pennsylvania | 1 | 705−5.5%/yr | −5.5%/yr | 0.5 | 0% | 710 in 2030+0.1%/yr |
| Massachusetts | 1 | 350−5.5%/yr | −5.5%/yr | 0.4 | 0% | 390 in 2030+1.8%/yr |
| Connecticut | 1 | 160−6.4%/yr | −6.4%/yr | 0.5 | 0% | 150 in 2030−0.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 55 | 8,709+2.3%/yr | +2.3%/yr | 8.01.8× | 77% | 12,700 in 2030+6.4%/yr |
| Dialysis access | 58 | 7,071−13%/yr | −13%/yr | 7.01.3× | 70% | 7,590 in 2030+1.2%/yr |
| Superficial venous ablation | 70 | 4,906−2.3%/yr | −2.3%/yr | 4.51.4× | 97% | 6,260 in 2030+4.1%/yr |
| Thrombectomy, IVC filters & venous stents | 25 | 1,782+1%/yr | +1%/yr | 1.71.3× | 28% | 1,690 in 2030−0.8%/yr |
| Carotid revascularization | 26 | 1,073−1.9%/yr | −1.9%/yr | 1.01.0× | 0% | 1,090 in 2030+0.2%/yr |
Aortic endografts (EVAR/TEVAR) in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with New York
Medtronic leads with 32% of company spending on these surgeons in 2025, +3 pts on 2024.
In 2025, 5 companies reported engagement with New Jersey’s surgeons worth $145K in consulting, speaking, meals and travel tied to these products, about $48K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 36 clearances and approvals in the category, 2 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.